# Initiation of ARNi and SGLT2i in Patients With HFrEF

> **NCT05989503** · PHASE4 · COMPLETED · sponsor: **Universidade do Porto** · enrollment: 62 (actual)

## Conditions studied

- Heart Failure With Reduced Ejection Fraction

## Interventions

- **DRUG:** Sacubitril-valsartan
- **DRUG:** SGLT2 inhibitor

## Key facts

- **NCT ID:** NCT05989503
- **Lead sponsor:** Universidade do Porto
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-08-04
- **Primary completion:** 2025-07-31
- **Final completion:** 2025-07-31
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2025-11-19

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05989503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05989503, "Initiation of ARNi and SGLT2i in Patients With HFrEF". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05989503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*